Exact Sciences Sep 23, 2022 In Brief This Week: Seagen, Ideaya Biosciences, Cellistic, AstraZeneca, Kinnate Biopharma Sep 12, 2022 ESMO Data Sharpens View of How Grail, Exact Sciences Multi-Cancer Early Detection Tests Perform Premium Aug 3, 2022 Exact Sciences Partners With West German Study Group to Validate MRD Test in Breast Cancer Aug 2, 2022 MDxHealth Acquires Prostate Cancer Testing Business From Exact Sciences for up to $100M Jun 8, 2022 Biomarker-Defined Subset of Early Breast Cancer Patients Can Avoid Radiation, ASCO Data Show May 12, 2022 ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making Premium Apr 28, 2022 ASCO Guideline Update Expands, Clarifies Use of Breast Cancer Adjuvant Treatment Test Apr 13, 2022 Guardant Health, Exact Sciences Make Progress on Multi-Cancer Detection Tests Premium Jan 13, 2022 JP Morgan Healthcare Conference Day 3: Iovance, Elevation Oncology, Autolus, and More Jan 10, 2022 Exact Sciences Projects up to $475M in Q4 Revenues, Acquires Testing Lab, Inks Licensing Deal Dec 9, 2021 RxPONDER Update Yields No Clear Guidance on Chemo Decisions for Younger Breast Cancer Patients Premium Oct 8, 2021 TGen Study Highlights Value of Repeat Tumor Profiling for Pediatric Solid Tumors Premium Sep 14, 2021 Exact Sciences, NSABP Validating Ability of ctDNA Test to Detect MRD in Colorectal Cancer Patients Apr 20, 2021 Prostate Cancer Study Shows Oncotype DX GPS Test Accurately Measures Long-Term Outcomes Premium Feb 17, 2021 Exact Sciences Sketches Out Strategy for End-to-End Cancer Testing With Ashion Acquisition Premium Feb 16, 2021 Exact Sciences Q4 Revenues up 58 Percent; Company to Acquire Ashion Analytics From TGen Jan 14, 2021 JP Morgan Healthcare, Day 3 and 4: ImmunoGen, Precigen, Autolus, Exact Sciences, Jounce, and More Jan 11, 2021 Multi-Cancer Molecular Screening Assays Primed for Clinical Implementation in 2021 Premium Jan 8, 2021 In Brief This Week: Genentech, Myriad Genetics, Merus, Ambrx, and More Dec 10, 2020 Exact Sciences Oncotype DX Identifies Postmenopausal Breast Cancer Patients Who Can Forgo Chemo Premium Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
